Prepared by Capital Hunter analysts
Venture capitalists, flush with readily available cash, have been on a tear the past few weeks, as weekly investment totals have been through the proverbial roof. Companies seeking funding this week raised a whopping $583 million, up nearly 15% from last week’s robust $513 million. The biggest reason(s) for the jump this week is due to a couple of abnormally large telecom investments. Amp’d Mobile, a mobile communications provider for teenagers and young professionals, raised an additional $150 million in third round funding, which brings the total amount raised by the company to over a quarter billion dollars since August of 2005. Another telecommunications company, Arcadian Networks, a provider of broadband wireless solutions to the utilities industry, raised $85 million from Goldman Sachs and Gilo Ventures. Together these companies accounted for over 40% of the week’s funding, which helped telecom investment to its highest weekly level since the apex of the dot-com era.
In other news, software, usually the most popular (along with biotechnology) sector for venture investment, managed to garner only 7% of the week’s funding, the lowest such total since 2005. Medical device investment was also down, as only $38 million placed into three companies, and $30 million of that amount was invested in a single company, AngioScore. Biotechnology investment remained strong, however, with over $100 million invested into such companies, accounting for almost 20% of the week’s funding. Other industries, such as networking equipment, consumer services, healthcare services, industrials, and business services received negligible investment.
IPO activity was relatively modest this week, with only three companies listing. The three companies are as follows:
JK Acquisition Corporation AMEX:JKA-U priced at
$58 million and is a blank-check company looking to acquire another company.
Vanda Pharmaceuticals NASDAQ:VNDA priced at
$57.5 million and is a provider of pharmaceuticals and therapeutics for central nervous system disorders.
Targacept NASDAQ:TRGT priced at
$45 million and is also a developer of drugs and therapeutics targeting the central nervous system.
Please come visit our web site at
CapitalHunter.com. We have made improvements to both the look and functionality of our web site, including business resources, glossary terms, and other helpful information provided free of charge for the budding entrepreneur. For private equity firms, consulting firms, business journals, and individuals looking to do research on venture backed companies, you can still gain complete access to our entire database for $59 a quarter and $199 a year.